Penetrance in Hereditary Cancer: Why a Variant Is Not a Diagnosis
Penetrance is the probability that a person carrying a pathogenic variant will develop the associated condition. For hereditary cancer genes it is almost never 100 percent, it varies by study, and it is modified by other factors, which is why a carrier result is a risk estimate rather than a prediction.
Quick Answer
Penetrance is the probability that a person carrying a pathogenic variant will develop the associated condition. For hereditary cancer genes it is almost never 100 percent, it varies by study, and it is modified by other factors, which is why a carrier result is a risk estimate rather than a prediction.
What Penetrance Is
If 100 carriers of a pathogenic variant are followed for life and 60 develop the associated cancer, the lifetime penetrance is 60 percent. Penetrance is usually expressed as a cumulative risk by a given age.
It is a population statistic. It does not tell an individual carrier whether they personally will be among those who develop cancer.
Why Estimates Vary
Early penetrance estimates often came from families selected because they had many affected members, which inflates the figure. Population-based and prospective studies generally give lower estimates.
For BRCA1 and BRCA2, large prospective cohorts converged on breast cancer risks around 65 to 75 percent by age 80, lower than some older family-based numbers. Moderate-risk genes show even wider ranges between studies.
Modifiers of Risk
Family history is the strongest readily available modifier: a carrier with several close affected relatives has a higher personal risk than a carrier with none. Common genetic variation, captured in polygenic risk scores, shifts risk further.
Hormonal, reproductive and lifestyle factors, and prior risk-reducing surgery, also change the estimate. This is why counselling uses individualised models rather than a single headline percentage.
Variable Expressivity
Even among carriers who develop cancer, the type, age of onset and severity differ. The same TP53 variant in one family may present with sarcoma in childhood and in another with breast cancer in adulthood.
Penetrance and expressivity are separate concepts: one is about whether disease occurs, the other about how it manifests.
Interpretation Notes
A carrier result should be paired with an individualised risk assessment through clinical genetics, not read as a fixed probability from a textbook.
Non-carriers in a family with a known pathogenic variant generally return to population-level risk, which is an important and reassuring part of cascade testing.
Key Takeaways
- ·Penetrance is the population probability that a carrier develops the associated condition.
- ·Family-based studies overestimate penetrance; population studies give lower figures.
- ·Family history and polygenic background substantially modify an individual's risk.
- ·Expressivity (how disease manifests) is separate from penetrance (whether it occurs).
Put these genes in pathway context
Frequently asked questions
What is the key idea in Penetrance in Hereditary Cancer: Why a Variant Is Not a Diagnosis?
Penetrance is the probability that a person carrying a pathogenic variant will develop the associated condition. For hereditary cancer genes it is almost never 100 percent, it varies by study, and it is modified by other factors, which is why a carrier result is a risk estimate rather than a prediction.
What should be kept with the result or mechanism?
Family-based studies overestimate penetrance; population studies give lower figures. Family history and polygenic background substantially modify an individual's risk. Expressivity (how disease manifests) is separate from penetrance (whether it occurs).
References
- 1Moderate penetrance genes complicate genetic testing for breast cancer diagnosis. The Breast, 2022. PubMed
- 2Cancer genetic counselling for hereditary breast cancer in the era of precision oncology. Cancer Treatment Reviews, 2024. PubMed
- 3Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA, 2017. PubMed
- 4Cancer genetics overview. National Cancer Institute, 2026. Source
Continue Reading
CHEK2 and Cancer Risk: A Moderate-Penetrance Gene
3 min read
Multigene Panel Testing for Hereditary Cancer: What It Adds
3 min read
Variant of Uncertain Significance: How to Read a VUS Result
2 min read
BRCA1 vs BRCA2: Different Roles in DNA Repair
2 min read
BRIP1 and Cancer Risk: What the Evidence Supports
3 min read
How to Read an Inherited-Cancer Genetic Testing Report
3 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
BRCA1 has 100+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.